Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Boraza G Ointment is a prescription topical medication developed and marketed by Amato Pharmaceutical Products in Japan for the treatment of hemorrhoids and anal fissures. It is a combination product containing two active ingredients: tribenoside and lidocaine. Tribenoside is a synthetic venotonic and anti-inflammatory agent that works by reducing capillary permeability, improving blood circulation in the anorectal region, and promoting wound repair. Lidocaine is a local anesthetic that provides rapid relief from pain, itching, and discomfort associated with anal conditions by blocking voltage-gated sodium channels. The ointment is indicated for relieving symptoms such as bleeding, pain, and swelling associated with blind piles and anal fissures. It is part of Amato's prescription drug line, distinguishing it from their over-the-counter Borraginol products.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Boraza G Ointment.